Related references
Note: Only part of the references are listed.Dexamethasone induces caveolin-1 in vascular endothelial cells: implications for attenuated responses to VEGF
Junsuke Igarashi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2013)
Quantification of circulating CD34+/KDR+/CD45dim endothelial progenitor cells: Analytical considerations
Emeline M. Van Craenenbroeck et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1
L. Mirandola et al.
LEUKEMIA (2013)
Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma
Archana Bhaskar et al.
LEUKEMIA & LYMPHOMA (2013)
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer
Yuichi Sakamori et al.
CANCER SCIENCE (2012)
Development of novel CXCR4-based therapeutics
Amnon Peled et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma
Archana Bhaskar et al.
LEUKEMIA & LYMPHOMA (2012)
Plerixafor A Review of its Use in Stem-Cell Mobilization in Patients with Lymphoma or Multiple Myeloma
Gillian M. Keating
DRUGS (2011)
CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth
Katia Beider et al.
EXPERIMENTAL HEMATOLOGY (2011)
A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients
Rajesh Rajpal et al.
PROTEOMICS (2011)
Cell-based methods for ex vivo evaluation of human endothelial biology
Gian Paolo Fadini et al.
CARDIOVASCULAR RESEARCH (2010)
Quantification of circulating endothelial progenitor cells in human peripheral blood: Establishing a reliable flow cytometry protocol
Behzad Kharabi Masouleh et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
Late Release of Circulating Endothelial Cells and Endothelial Progenitor Cells after Chemotherapy Predicts Response and Survival in Cancer Patients
J. M. Roodhart et al.
NEOPLASIA (2010)
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Abdel Kareem Azab et al.
BLOOD (2009)
Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells
Seong-Woo Kim et al.
LEUKEMIA & LYMPHOMA (2009)
The stromal derived factor-1\CXCR4 axis - a legitimate therapeutic target in multiple myeloma?
Ben-Zion Katz et al.
LEUKEMIA & LYMPHOMA (2009)
Thalidomide treatment down-regulates SDF-1α and CXCR4 expression in multiple myeloma patients
Adriana Morgan Oliveira et al.
LEUKEMIA RESEARCH (2009)
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model
Haiqing Li et al.
BJU INTERNATIONAL (2008)
Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma
Sally K. Martin et al.
CLINICAL CANCER RESEARCH (2006)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells
M Grunewald et al.
CELL (2006)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
AM Roccaro et al.
CANCER RESEARCH (2006)
Circulating endothelial progenitor cells in multiple myeloma:: implications and significance
H Zhang et al.
BLOOD (2005)
Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients
ACW Zannettino et al.
CANCER RESEARCH (2005)
Share Paper
